April 30th 2024
During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lee Reviews Trials Supporting IO/TKI Combinations in Frontline RCC
September 23rd 2022During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of lenvatinib/pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma.
Read More
Choosing Frontline RCC Therapy After Detecting Metastases in Patient Under Observation
September 12th 2022During a Targeted Oncology case-based roundtable event, Sumanta K. Pal, MD, discussed the choice of frontline therapy for a favorable-risk patient with advanced clear cell renal cell carcinoma.
Read More
Belzutifan/Cabozantinib Combo is Well Tolerated in Treatment-Naïve Advanced Clear Cell RCC
September 12th 2022The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.
Read More
Tailoring Nivolumab and Ipilimumab Therapy Leads to Better Responses in RCC
September 11th 2022A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.
Read More
Additional Follow-up for CLEAR Trial Shows Maintained Lenvatinib/Pembrolizumab Benefit in RCC
September 11th 2022Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.
Read More
No Significant Improvement of DFS Seen in High-Risk RCC With Adjuvant Nivolumab/Ipilimumab
September 11th 2022Adjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk for relapse after nephrectomy failed to significantly improve disease-free survival vs placebo in part A of the phase 3 CheckMate 914 trial.
Read More
Eligibility for Adjuvant Pembrolizumab in RCC: Real-World Vs KEYNOTE-564
September 1st 2022Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.
Watch